HeartSciences Inc. Cash Flow Statement
HSCS|3 years of annual SEC 10-K data (FY2023-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
HeartSciences Inc. used $6M in operating cash flow and negative free cash flow of $6M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -5.89 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Net Income | -$6.6M | -$6.4M | -$4.8M |
| Depreciation & Amortization | $27.9K | $26.9K | $26.6K |
| Operating Cash Flow | -$6.1M | -$5.8M | -$3.6M |
| Capital Expenditures | $64.5K | $18.3K | $1.9K |
| Free Cash Flow | -$6.1M | -$5.8M | -$3.6M |
| FCF Margin | -32981.9% | -112463.8% | -25367.5% |